IP Library Granted Patent US 9,127,256
Granted Patent B2
US 9,127,256 · App. 13/054,022 · Granted Sep 8, 2015

Method for production of reprogrammed cell using chromosomally unintegrated virus vector

Inventors: Noemi Fusaki (Ibaraki, JP); Hiroshi Ban (Ibaraki, JP); Mamoru Hasegawa (Ibaraki, JP); Yoshikazu Yonemitsu (Chiba, JP)
Assignee: DNAVEC CORPORATION
C12N5/0696C07K14/4702C12N2501/60C12N2501/602C12N2501/603C12N2501/604C12N2501/606C12N2510/00C12N2760/18622C12N2760/18643C12N2760/18645C12N2760/18662
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,127,256
App. No.
13/054,022
Granted
Sep 8, 2015
Kind
B2
Abstract

An objective of the present invention is to provide vectors for conveniently and efficiently producing ES-like cells in which foreign genes are not integrated into the chromosome. The present inventors discovered methods for producing ES-like cells from somatic cells using chromosomally non-integrating viral vectors. Since no foreign gene is integrated into the chromosome of the produced ES-like cells, they are advantageous in tests and research, and immunological rejection and ethical problems can be avoided in disease treatments.

Claims (4)

1. A method of producing an induced pluripotent stem cell (iPSC), comprising introducing one or more Sendai virus vectors encoding at least Oct3/4 and Sox2 into a differentiated cell, and culturing said cell under conditions to obtain a reprogrammed iPSC.

2. The method of claim 1 , wherein said one or more Sendai virus vectors encodes at least Oct3/4, Klf4, and Sox2, or at least Oct3/4, Sox2, Nanog, and Lin28.

3. The method of claim 1 , wherein said one or more Sendai virus vectors encodes at least Oct3/4, Klf4, Sox2, and c-Myc, or at least Oct3/4, Klf4, Sox2, and L-Myc.

4. The method of claim 1 , wherein said one or more Sendai virus vectors are temperature sensitive Sendai virus vectors, and wherein said method further comprises removing said one or more Sendai virus vectors by culturing the cell at 37.5° C. to 39° C. after reprogramming.

Assignments (2)
CHANGE OF NAME Recorded Nov 6, 2015
From: DNAVEC CORPORATION
To: ID PHARMA CO., LTD.
Reel/Frame 037065/0686 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 8, 2011
From: FUSAKI, NOEMI; BAN, HIROSHI; HASEGAWA, MAMORU; YONEMITSU, YOSHIKAZU
To: DNAVEC CORPORATION
Reel/Frame 026714/0236 →
Priority Claims (3)
JP 2008-185049 · Jul 16, 2008 · national
JP 2008-258883 · Oct 3, 2008 · national
JP 2009-126753 · May 26, 2009 · national
Continuity (1)
Related Publication 20110287538A1 · Nov 24, 2011